

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.\* Announcement on the Participation in the 2023 Annual Results Briefing for the STAR Market Pharmaceutical Session and the 2024 First Quarterly Results Briefing” (《上海君實生物醫藥科技股份有限公司關於參加2023年度科創板製藥專場集體業績說明會暨2024年第一季度業績說明會的公告》) published by Shanghai Junshi Biosciences Co., Ltd.\* on the website of the Shanghai Stock Exchange, which is for reference purpose only.

By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 13 May 2024

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun, Dr. Wang Gang and Dr. Li Xin as executive directors; Dr. Feng Hui and Mr. Tang Yi as non-executive directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive directors.*

\* For identification purpose only

**Shanghai Junshi Biosciences Co., Ltd.\***  
**Announcement on the Participation in the 2023**  
**Annual Results Briefing for the STAR Market**  
**Pharmaceutical Session and the 2024 First Quarterly**  
**Results Briefing**

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

**Important Notice:**

- Time of the briefing: 15:00-17:00, 20 May 2024 (Monday)
- Venue of the briefing: SSE Roadshow Center (<http://roadshow.sseinfo.com>)
- Mode of the briefing: Online interactive text
- Investors are invited to send questions of interest to the email of Shanghai Junshi Biosciences Co., Ltd.\* (the “Company”) ([info@junshipharma.com](mailto:info@junshipharma.com)) before 16:00 on 17 May 2024 (Friday). The Company will respond to questions that are of general concern to investors at the briefing.

The Company has disclosed its 2023 annual report and 2024 first quarterly report on the website of the Shanghai Stock Exchange ([www.sse.com.cn](http://www.sse.com.cn)) on 29 March 2024 and 30 April 2024, respectively. In order to facilitate investors to have a more comprehensive and in-depth understanding of the operating results, financial status, development vision of the Company for 2023 and the first quarter of 2024, the Company will participate in the 2023 annual results briefing for the STAR Market pharmaceuticals hosted by the Shanghai Stock Exchange. Online interactive text will be adopted for the event and investors can log into the SSE Roadshow Center of the

Shanghai Stock Exchange (<http://roadshow.sseinfo.com/>) to participate in the online interactive event.

### **I. Type of the Briefing**

This investor briefing will be held in the form of online interactive text. The Company will interact and communicate with investors with regard to the operating results and specific financial indicators for 2023 and the first quarter of 2024. Questions that are of general concern to investors will be answered subject to restrictions under the information disclosure rules.

### **II. Time, Mode and Venue of the Briefing**

(I) Time of the briefing: 15:00-17:00, 20 May 2024 (Monday)

(II) Venue of the briefing: SSE Roadshow Center ([http://roadshow.sseinfo.com](http://roadshow.sseinfo.com/))

(III) Mode of the briefing: Online interactive text

(IV) Investors are invited to send questions of interest to the email of the Company ([info@junshipharma.com](mailto:info@junshipharma.com)) before 16:00 on 17 May 2024 (Friday). The Company will respond to questions that are of general concern to investors at the briefing.

### **III. Attendees**

Attendees of the briefing include: Ms. Zou Jianjun (Executive Director, General Manager and Chief Executive Officer), Mr. Zhang Chun (Independent Non-Executive Director), Mr. Xu Baohong (Financial Director), and Mr. Wang Zhengyu (Secretary of the Board of Directors) (subject to changes in case of any special circumstances).

### **IV. Contact Details for the Briefing**

Contact Department: Securities Department

Contact Tel.: 021-61058800-1153

Contact Email: [info@junshipharma.com](mailto:info@junshipharma.com)

### **V. Others Matters**

Upon the convening of the investor briefing, investors may review the convening details and key contents of the investor briefing at the website of the SSE Roadshow Center (<http://roadshow.sseinfo.com/>).

Notice is hereby given.

Shanghai Junshi Biosciences Co., Ltd.\*

Board of Directors

14 May 2024

*\*For identification purpose only*